Aging does not impact safety and efficacy of biologic or targeted synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
Abstract Background The study compared biologic (b) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs) efficacy and safety in elderly rheumatoid arthritis (RA) patients over a period of 1 year. Results This retrospective study included 52 RA patients. At baseline elderly pati...
Saved in:
| Main Authors: | Yasemin Tombak, Ajda Bal, Emel Eksioglu, Nihan Abidin, Ozgur Zeliha Karaahmet, Deniz Dulgeroglu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2025-06-01
|
| Series: | Egyptian Rheumatology and Rehabilitation |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43166-025-00336-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effectiveness and patient-reported impact of on-flare retreatment in patients with rheumatoid arthritis: insights from retrospective long-term real-world data
by: Delphine Bertrand, et al.
Published: (2025-07-01) -
Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region
by: Zoltán Kaló, et al.
Published: (2017-01-01) -
Secukinumab Persistence in Patients with Psoriatic Arthritis: An Adalimumab-Matched Retrospective Cohort Database Study (FLYWAY)
by: Hideto Kameda, et al.
Published: (2025-03-01) -
Rheumatoid arthritis and COVID-19: Three years later
by: B. S. Belov, et al.
Published: (2023-08-01) -
Tuberculosis infection in patients with rheumatic diseases under different treatments
by: Tianhui Liu, et al.
Published: (2025-05-01)